February 12, 2024•
The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar, adding a treatment for chronic liver disease to its portfolio.
Last modified: February 12, 2024
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Δ
This site uses Akismet to reduce spam. Learn how your comment data is processed.
